Sarepta Therapeutics (NASDAQ:SRPT) Sets New 1-Year Low - Should You Sell?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) reached a new 52-week low during trading on Tuesday . The stock traded as low as $72.17 and last traded at $73.38, with a volume of 770178 shares traded. The stock had previously closed at $76.33.

Analyst Ratings Changes

Several research firms recently issued reports on SRPT. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a report on Wednesday, March 19th. Royal Bank of Canada dropped their target price on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating for the company in a report on Thursday, February 27th. Scotiabank decreased their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a report on Thursday, March 20th. HC Wainwright reiterated a "sell" rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, March 19th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $167.41.

Remove Ads

Sarepta Therapeutics Trading Down 1.9 %

The company's 50-day moving average is $102.66 and its 200 day moving average is $115.99. The company has a market cap of $6.83 billion, a price-to-earnings ratio of 56.33 and a beta of 0.79. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Insiders Place Their Bets

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 7.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SRPT. Daiwa Securities Group Inc. grew its stake in shares of Sarepta Therapeutics by 13.8% in the 3rd quarter. Daiwa Securities Group Inc. now owns 3,929 shares of the biotechnology company's stock valued at $490,000 after buying an additional 475 shares during the period. Fisher Asset Management LLC grew its position in Sarepta Therapeutics by 1.3% in the third quarter. Fisher Asset Management LLC now owns 18,155 shares of the biotechnology company's stock worth $2,267,000 after acquiring an additional 239 shares during the period. Quantbot Technologies LP acquired a new stake in Sarepta Therapeutics during the third quarter worth $237,000. Blueshift Asset Management LLC purchased a new stake in Sarepta Therapeutics in the third quarter valued at $262,000. Finally, Alkeon Capital Management LLC raised its position in Sarepta Therapeutics by 13.4% in the third quarter. Alkeon Capital Management LLC now owns 633,845 shares of the biotechnology company's stock valued at $79,161,000 after purchasing an additional 75,000 shares during the period. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.